Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

hypochlorous acid

- PMLiVE

Dermavant’s Vtama shows promise in paediatric atopic dermatitis trial

The trial included children aged between two to 17 years and the treatment was well tolerated

- PMLiVE

Almirall granted EMA approval for lebrikizumab in atopic dermatitis

The Marketing Authorization Application is based on three pivotal phase 3 studies

- PMLiVE

Almirall shares positive topline results from atopic dermatitis trials

The company plans to submit a Marketing Authorisation Application to the EMA later this year

- PMLiVE

AbbVie’s Rinvoq accepted by SMC for atopic dermatitis

Scotland is the first nation in the UK to approve NHS access for the drug

- PMLiVE

Lebrikizumab achieves skin clearance in pivotal phase 3 atopic dermatitis trials

More than 50% of patients with moderate-to-severe atopic dermatitis experienced at least a 75% reduction in disease severity at 16 weeks

- PMLiVE

Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis

The FDA based its approval on results from a clinical trial programme involving over 1,600 patients

- PMLiVE

Pfizer buys Arena in $6.7bn deal to broaden immuno-inflammatory portfolio

The cash deal includes Arena’s lead candidate, etrasimod, which is currently in trials for ulcerative colitis, Crohn’s disease and atopic dermatitis

- PMLiVE

Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology

Avalere Health

- PMLiVE

Tocagen merges with Forte Biosciences after brain cancer fail

New company will focus on Forte's lead skin disease drug

- PMLiVE

Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year

- PMLiVE

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

Therapy candidate was licensed in a $1bn-plus deal last year

- PMLiVE

Realm toppled by second mid-stage trial flop

The hypochlorous acid gel failed to show EASI score improvement compared to placebo

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links